Home › Multiple Sclerosis › Texas › Plano
Multiple Sclerosis clinical trials in Plano, TX
3 studies for Multiple Sclerosis are looking for participants at sites in and around Plano (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RecruitingPhase 3
- North Texas Institute of Neurology & Headache - Plano- Site Number : 8400082, Plano
- North Texas Institute of Neurology & Headache - Plano- Site Number : 8400083, Plano
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
RecruitingPhase 3
- Saturn Research Solution, Plano
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RecruitingPhase 2
- Saturn Research Solutions, Plano
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH10 studies
- Birmingham, AL9 studies
- Aurora, CO8 studies
- Kansas City, KS8 studies
- St. Louis, MO8 studies
- San Francisco, CA8 studies
- Tampa, FL7 studies
- Dallas, TX7 studies
Other studies in Plano
- Heart Failure13 studies
- Cardiovascular Disease10 studies
- Coronary Artery Disease9 studies
- Aortic Valve Stenosis5 studies
- Non-Small Cell Lung Cancer4 studies
- Obesity4 studies
- Heart Diseases4 studies
- Depression4 studies
- Schizophrenia3 studies
- Tricuspid Valve Insufficiency3 studies
- Hypertrophic Cardiomyopathy3 studies
- Angina3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.